Trial Profile
A Phase II Trial of Radiotherapy (RT)-Durvalumab Without Prophylactic Neck Irradiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms REWRITe
- Sponsors Groupe Oncologie Radiotherapie Tete et Cou
- 22 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2022 Planned End Date changed from 1 Dec 2024 to 1 Aug 2026.
- 10 Mar 2022 Planned primary completion date changed from 1 Feb 2024 to 1 Jul 2026.